GIPR and diabetes mellitus: The most extensively studied scenario concerns the antidiabetic effects of Pro(3)GIP described by the Coleraine group where, unlike GIPR agonists, amelioration of diabetes is associated with lower rather than raised insulin concentrations [272,280].